Profile data is unavailable for this security.
About the company
Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company is into exploring strategic alternatives to maximize stockholder value. It is engaging in a broader exploration of strategic alternatives. This effort involves exploring growth through transactions with potential partners that see opportunity in joining an existing, publicly traded organization. The Company is exploring transactions in industries unrelated to its historical operations. It does not generate any revenues. It wholly owned subsidiary is Exicure Operating Company that holds all material assets and conducts all business activities and operations of the Company.
- Revenue in USD (TTM)500.00k
- Net income in USD-4.01m
- Incorporated2017
- Employees6.00
- LocationExicure Inc2430 N. HALSTED ST.CHICAGO 60614United StatesUSA
- Phone+1 (847) 673-1700
- Fax+1 (847) 556-6411
- Websitehttps://www.exicuretx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aeon Biopharma Inc | 0.00 | -350.57m | 22.27m | 5.00 | -- | -- | -- | -- | -9.61 | -9.61 | 0.00 | -0.8106 | 0.00 | -- | -- | 0.00 | -3,242.54 | -- | -- | -- | -- | -- | -- | -- | -- | 2.94 | -- | -- | -- | -- | -631.85 | -- | -- | -- |
| Acurx Pharmaceuticals Inc | 0.00 | -16.44m | 22.58m | 4.00 | -- | 8.75 | -- | -- | -1.09 | -1.09 | 0.00 | 0.1589 | 0.00 | -- | -- | 0.00 | -250.15 | -- | -498.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.55 | -- | -- | -- |
| Tempest Therapeutics Inc | 0.00 | -35.52m | 22.65m | 17.00 | -- | 2.08 | -- | -- | -1.57 | -1.57 | 0.00 | 0.4313 | 0.00 | -- | -- | 0.00 | -122.85 | -57.10 | -195.00 | -71.20 | -- | -- | -- | -- | -- | -- | 0.426 | -- | -- | -- | 17.41 | -- | 36.40 | -- |
| Eom Pharmaceutical Holdings Inc | 0.00 | -4.93m | 22.65m | 3.00 | -- | -- | -- | -- | -0.0435 | -0.0435 | 0.00 | -0.0212 | -- | -- | -- | 0.00 | -- | -126.34 | -- | -171.37 | -- | -- | -- | -- | -- | -- | 7.41 | -- | -- | -- | -254.37 | -- | -- | -- |
| Ocean Biomedical Inc | 0.00 | -98.59m | 23.91m | 9.00 | -- | -- | -- | -- | -3.01 | -3.01 | 0.00 | -2.21 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.2443 | -- | -- | -- | -- | 72.16 | -- | -- | -- |
| Cadrenal Therapeutics Inc | 0.00 | -7.61m | 24.05m | 4.00 | -- | 5.25 | -- | -- | -7.05 | -7.05 | 0.00 | 2.76 | 0.00 | -- | -- | 0.00 | -108.76 | -- | -125.13 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.47 | -- | -- | -- |
| Exicure Inc | 500.00k | -4.01m | 24.31m | 6.00 | -- | 15.73 | -- | 48.62 | -2.26 | -2.26 | 0.282 | 0.7112 | 0.0424 | -- | 0.4852 | 83,333.34 | -33.98 | -41.52 | -45.26 | -55.78 | -- | -- | -801.40 | -290.95 | -- | -- | 0.00 | -- | -100.00 | -- | -555.07 | -- | -- | -- |
| Lisata Therapeutics Inc | 0.00 | -20.74m | 24.38m | 25.00 | -- | 0.7236 | -- | -- | -2.51 | -2.51 | 0.00 | 4.05 | 0.00 | -- | -- | 0.00 | -43.08 | -45.97 | -47.69 | -50.47 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 61.57 | -- | -- | -- |
| Cell Source Inc | 0.00 | -6.57m | 24.48m | -- | -- | -- | -- | -- | -0.1613 | -0.1613 | 0.00 | -0.4379 | 0.00 | -- | -- | -- | -2,039.39 | -1,758.85 | -- | -- | -- | -- | -- | -- | -- | -3.74 | -- | -- | -- | -- | -3.55 | -- | -- | -- |
| Geovax Labs Inc | 3.09m | -24.32m | 24.63m | 17.00 | -- | 2.64 | -- | 7.97 | -9.21 | -9.21 | 0.9299 | 0.9878 | 0.2263 | -- | -- | 181,774.10 | -178.10 | -108.34 | -276.02 | -147.24 | -- | -- | -787.08 | -1,842.93 | -- | -- | 0.00 | -- | -100.00 | -- | -85.20 | -- | -- | -- |
| Athira Pharma Inc | 0.00 | -109.22m | 24.69m | 65.00 | -- | 0.4313 | -- | -- | -2.85 | -2.85 | 0.00 | 1.49 | 0.00 | -- | -- | 0.00 | -80.62 | -30.73 | -101.80 | -32.46 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.04 | -- | -- | -- |
| Lipocine Inc | 7.92m | -4.06m | 25.19m | 17.00 | -- | 1.32 | -- | 3.18 | -0.7626 | -0.7626 | 1.48 | 3.57 | 0.3486 | -- | 119.56 | 466,054.70 | -17.85 | -39.32 | -19.49 | -45.87 | -- | -- | -51.19 | -442.26 | -- | -- | 0.00 | -- | -670.16 | -- | -51.99 | -- | -- | -- |
| Equillium Inc | 45.91m | -4.62m | 25.44m | 45.00 | -- | 1.10 | -- | 0.554 | -0.1316 | -0.1316 | 1.29 | 0.6543 | 1.02 | -- | 10.46 | 1,043,500.00 | -10.29 | -46.81 | -18.30 | -57.36 | -- | -- | -10.05 | -328.35 | -- | -- | 0.00 | -- | 128.97 | -- | 78.64 | -- | 7.48 | -- |
| IGC Pharma Inc | 1.18m | -12.57m | 25.81m | 67.00 | -- | 3.46 | -- | 21.82 | -0.1879 | -0.1879 | 0.0171 | 0.0963 | 0.088 | 0.2499 | 13.07 | 17,656.72 | -93.54 | -42.46 | -114.44 | -46.07 | 56.21 | 20.95 | -1,062.47 | -730.00 | 0.9779 | -- | 0.0184 | -- | 47.64 | -23.45 | -12.98 | -- | 53.72 | -- |
Data as of Nov 21 2024. Currency figures normalised to Exicure Inc's reporting currency: US Dollar USD
2.12%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| HRT Financial LP (US)as of 30 Sep 2024 | 14.48k | 0.84% |
| Northwestern University (Investment Management)as of 30 Sep 2024 | 10.43k | 0.60% |
| UBS Securities LLCas of 30 Sep 2024 | 9.25k | 0.53% |
| Tower Research Capital LLCas of 30 Sep 2024 | 1.41k | 0.08% |
| Morgan Stanley & Co. LLCas of 30 Sep 2024 | 483.00 | 0.03% |
| UBS Financial Services, Inc.as of 30 Sep 2024 | 342.00 | 0.02% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Sep 2024 | 162.00 | 0.01% |
| BofA Securities, Inc.as of 30 Sep 2024 | 103.00 | 0.01% |
| Osaic Wealth, Inc. (Investment Management)as of 30 Sep 2024 | 59.00 | 0.00% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 35.00 | 0.00% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
